MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
about
New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cellsBurkitt lymphoma: pathogenesis and immune evasion.Virus and cell RNAs expressed during Epstein-Barr virus replicationInactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies.Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumorsLong-term latent murine Gammaherpesvirus 68 infection is preferentially found within the surface immunoglobulin D-negative subset of splenic B cells in vivo.To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesisHLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognitionT cell-based therapies for EBV-associated malignancies.Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system.EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cellsControl of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.Immune escape by Epstein-Barr virus associated malignancies.c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.Mutations in components of antiviral or microbial defense as a basis for breast cancer.Epstein-Barr virus and Burkitt lymphoma.Functional analysis and molecular characterization of spontaneously outgrown human lymphoblastoid cell lines.Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.Recent advances in understanding Epstein-Barr virus.c-Myc and EBV-LMP1: two opposing regulators of the HLA class I antigen presentation machinery in epithelial cellsLongitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation.C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF.Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation.Pathways accessory to proteasomal proteolysis are less efficient in major histocompatibility complex class I antigen production.c-Myc Represses Transcription of the Epstein-Barr Virus Latent Membrane Protein 1 Early After Primary B Cell Infection.
P2860
Q28534587-3061F4C9-E861-4C23-932C-0C3526BA723AQ34189497-D2163162-EF51-45A4-9C0D-B471522946F9Q34434702-0722478F-5285-4F32-9331-513DA2F53BA5Q34725050-3970BBC4-C9F3-4C0F-81C2-4557DE87544CQ35071179-116F0CC1-71E3-49E5-A5F5-537927F25F0AQ35155237-56702075-7379-4D04-85AA-F6D15CF04CAEQ35581465-9BE7B487-A927-446D-A18A-B2ED422ADF1BQ35582198-C323BDF4-DDF5-466D-A397-6EEE51BC43D5Q35609768-BB8BBF68-3039-45D2-9149-0340BB4A5D46Q35691576-FA88F520-85A1-4B03-A2CF-A911BD26A316Q35784734-AC0435D1-1F26-4829-AB87-58506F8B4B41Q36228567-6D1C16EA-A3EC-440D-A0A5-84BE804DE90CQ37041507-BFAA4506-08CF-40DE-9261-AD1EC95D5F6FQ37192244-1CBFC736-384E-4D43-B469-261857939185Q38140679-516822EC-D764-4EDF-8618-72D079C4A6BEQ38270680-DCF42ECE-1FE2-48C4-BFA1-ED89F66F92E9Q38974233-0955D353-79AC-417B-87F5-E25F3BF81304Q39015659-61C663D8-1AA2-48E9-B2DF-EB1F3399E869Q39241944-4AA3225D-30E9-45C9-AE5B-9C17FD3DDDDDQ39347865-303788C5-07FE-4B8F-ACF2-8929C83BCDBFQ39441043-AD45A9A3-9507-4A2D-8A8E-710C0B8541D5Q40185161-73D26E33-8890-4A42-BF43-F2E1440B8A51Q40274387-2123C7B9-58D5-4459-B266-261C39B30F16Q40705440-729B35CB-B9AC-47A3-88F5-9C177BC4E7A0Q42701290-FBD1D646-6B55-4B42-9529-3613732B8760Q44253376-2B8AC732-C04A-4A0A-9E3B-CE1EF374A5D9Q45325105-DA88CEB6-48B8-431F-BF9A-3F7BF773E22C
P2860
MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@ast
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@en
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@nl
type
label
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@ast
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@en
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@nl
prefLabel
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@ast
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@en
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@nl
P2093
P2860
P50
P356
P1476
MYC overexpression imposes a n ...... n-Barr virus-infected B cells.
@en
P2093
Alan B Rickinson
Alexander Pajic
Axel Polack
Siegfried Scholz
Steven P Lee
Teresa Frisan
P2860
P304
P356
10.1073/PNAS.072495599
P407
P577
2002-03-26T00:00:00Z